GlassScriptPhysician profile
Rhonda Hardy
NPI 1477942894
$1,094.68
in general payments reported to CMS, 2019-2025
23 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $207 · 2023: $279 · 2024: $265 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $141.19 | 2023-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.11 | 2021-2024 | Jardiance, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $118.20 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $100.27 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $80.61 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Daiichi Sankyo INC. | $76.58 | 2021-2023 | Injectafer |
| Glaxosmithkline, LLC. | $74.45 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $55.23 | 2022-2025 | |
| Abbvie INC. | $41.33 | 2024-2025 | |
| Amgen INC. | $30.38 | 2023 | Repatha, Otezla, Prolia |
| Phathom Pharmaceuticals, INC. | $30.09 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $29.17 | 2021-2022 | |
| Exact Sciences Corporation | $22.09 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $20.57 | 2025 | Yupelri |
| Ironshore Pharmaceuticals INC. | $20.12 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $17.96 | 2023 | Slynd |
| Otsuka America Pharmaceutical, INC. | $17.00 | 2024 | Rexulti |
| Astellas Pharma US INC | $15.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.74 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2021 | |
| Dexcom, INC. | $14.38 | 2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.48 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.